Chargement en cours...
Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network
Bevacizumab significantly extends progression-free survival (PFS) and overall survival (OS) times when combined with initial chemotherapy and continued as monotherapy until disease progression or unacceptable toxicity in patients with nonsquamous non-small cell lung cancer (NSCLC). In clinical pract...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
AlphaMed Press
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228113/ https://ncbi.nlm.nih.gov/pubmed/21441299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0287 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|